Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, MacDougald OA, You M, Williams BO, Guan KL.

Cell. 2006 Sep 8;126(5):955-68.


Mind the GAP: Wnt steps onto the mTORC1 train.

Choo AY, Roux PP, Blenis J.

Cell. 2006 Sep 8;126(5):834-6.


A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.

Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, Inoki K, Guan KL, Brosius FC 3rd.

Am J Physiol Cell Physiol. 2008 Sep;295(3):C836-43. doi: 10.1152/ajpcell.00554.2007.


Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.

Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL.

Clin Cancer Res. 2008 May 1;14(9):2543-50. doi: 10.1158/1078-0432.CCR-07-0321.


Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.

Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N.

J Biol Chem. 2005 Sep 16;280(37):32081-9.


LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.

Shaw RJ.

Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Review.


Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88.


Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Inoki K, Li Y, Xu T, Guan KL.

Genes Dev. 2003 Aug 1;17(15):1829-34.


Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL.

Genes Dev. 2004 Jul 1;18(13):1533-8.


Aberrant beta-catenin signaling in tuberous sclerosis.

Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS.

Am J Pathol. 2005 Jul;167(1):107-16.


The coordinate regulation of the p53 and mTOR pathways in cells.

Feng Z, Zhang H, Levine AJ, Jin S.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9.


Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis.

Lacher MD, Pincheira R, Zhu Z, Camoretti-Mercado B, Matli M, Warren RS, Castro AF.

Oncogene. 2010 Dec 16;29(50):6543-56. doi: 10.1038/onc.2010.393.


Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.

Yang J, Kalogerou M, Samsel PA, Zhang Y, Griffiths DF, Gallacher J, Sampson JR, Shen MH.

Oncogene. 2015 Feb 12;34(7):922-31. doi: 10.1038/onc.2014.17.


Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.


Hypoxia-induced energy stress regulates mRNA translation and cell growth.

Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC.

Mol Cell. 2006 Feb 17;21(4):521-31.


Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.

Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7.


The LKB1 tumor suppressor negatively regulates mTOR signaling.

Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC.

Cancer Cell. 2004 Jul;6(1):91-9.


Supplemental Content

Support Center